Evidence & regulatory context
- Mechanism
- No mechanism-of-action record in ChEMBL (metabolic substrate rather than target-directed agent)
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- 1982
- Development stage
- Not recorded
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Dextrose; Glucose; D-glucose, anhydrous; Anhydrous dextrose; D5W; B05CX01
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatTBIControlled cortical impactSprague DawleyMalen = 77 male rats in total. Experiment 1: Sham-SAL n = 10, Sham-…Intraperitoneal2.0 g/kg as a 50% solution in 0.9% salineExperiment 1: single injection immediately after injury. Experiment 2: injectio…
Model: Unilateral controlled cortical impact: 6 mm craniotomy centred 3 mm posterior to bregma and 3.5 mm left lateral, pneumatic dual-stroke piston with 5 mm flat-tipped impactor at 20 psi and 2.30 to 2.40 m/s, 2 mm depth for 250 ms
A single post-injury glucose dose raised blood glucose from 8.5 to 19.5 mmol/L at 10 min and attenuated the injury-induced depression of cerebral glucose metabolism in 4 of 6 cortical and 2 of 7 subcortical regions, with significantly fewer Fluoro-Jade B positive neurons in cortex (P = 0.05), hilus…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.